A multiplex immunoassay of serum biomarkers for the detection of uveal melanoma
Abstract Background Approximately 50% of uveal melanoma (UM) patients develop metastases preferentially in the liver leading to death within 15 months. Currently, there is no effective treatment for metastatic UM, in part because the tumor burden is typically high when liver metastases are detected...
Main Authors: | Jin Song, Shannath L. Merbs, Lori J. Sokoll, Daniel W. Chan, Zhen Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-03-01
|
Series: | Clinical Proteomics |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12014-019-9230-8 |
Similar Items
-
Validation of Serum Biomarkers That Complement CA19-9 in Detecting Early Pancreatic Cancer Using Electrochemiluminescent-Based Multiplex Immunoassays
by: Jin Song, et al.
Published: (2021-12-01) -
Blood Biomarkers of Uveal Melanoma: Current Perspectives
by: Bande Rodríguez MF, et al.
Published: (2020-01-01) -
S100 as Serum Tumor Marker in Advanced Uveal Melanoma
by: Martin Salzmann, et al.
Published: (2023-03-01) -
Impact of Genetic Ancestry on Prognostic Biomarkers in Uveal Melanoma
by: Daniel A. Rodriguez, et al.
Published: (2020-10-01) -
Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma
by: Wen-Da Zhou, et al.
Published: (2022-03-01)